Trial Profile
A Phase Ib, Open-label Study of Alpelisib (BYL719) in Combination With Cisplatin in Patients With HPV+ Solid Tumor Malignancies
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 03 Oct 2021
Price :
$35
*
At a glance
- Drugs Alpelisib (Primary) ; Cisplatin
- Indications Advanced breast cancer; Anal cancer; Cervical cancer; Endometrial cancer; Penile cancer; Prostate cancer; Solid tumours
- Focus Adverse reactions
- 08 Jun 2021 Results presented at the 57th Annual Meeting of the American Society of Clinical Oncology
- 07 Jan 2020 Status changed from recruiting to discontinued.
- 18 Jan 2018 Planned end date changed from 1 Mar 2018 to 1 Mar 2020.